依贝沙坦与卡托普利联合治疗充血性心力衰竭的疗效

Captopril combined with irbesartan in treating patients with congestive heart failure

目的:研究依贝沙坦与卡托普利联合治疗充血性心力衰竭(CHF)与单用卡托普利的疗效.方法:CHF患者120例在应用利尿剂、β受体阻断剂、洋地黄治疗的基础上,分为A组(n=60)口服依贝沙坦75～300 mg/d,卡托普利75～150mg/d;B组(n=60)口服卡托普利50～150 mg/d.治疗前后进行心功能NYHA分级评估,行血生化、肝肾功能、心电图、超声心动图检查.结果:治疗12 wk后两组左房内径(LA),左室舒张末内径(LVDD),左室收缩末内径(LVSD),左室射血分数(EF)均有改善(P＜0.01).A组LVDD,LVSD,EF及心功能改善总有效率比B组更显著(P＜0.05).两组治疗后不良反应发生率有明显差异(P＜0.05).结论:依贝沙坦与卡托普利联合治疗CHF优于单用卡托普利.

AIM： To evaluate the effects of captopril combined with irbesartan in treating patients with congestive heart failure （CHF）. METHODS： One hundred and twenty patients, who had unsatisfactory results by conventional treatment of digitalis, diuretics and β-blocking agent, were randomly divided into group A and group B. Group A （ n = 60） was given captoprU 50 - 150 mg/d and irbesartan 75 - 300 mg/d and Group B （ n = 60） was given captopril 50 - 150 mg/d. The changes of NYHA class, biochemistry, liver function, renal function, electrocardiogram and echocardiography were observed. RESULTS： After 12 weeks＇ treatment, left atrium （LA） diameter, left ventricular end diastolic diameter（ LVDD）, left ventricular end systolic diameter （LVSD） and left ventricular ejection fraction （EF） were improved significantly in both groups （ P 〈 0.0l ）. LVDD, LVSD EF and NYHA class were more significant in group A than those in group B （ P 〈 0.05）. There was a significant difference of adverse reaction before and after the treatment between the 2 groups （ P 〈 0.05）. CONCLUSION： I rbesartan combined with captopril is more effective than captopril alone in the treatment of patients with CHF.